RGNX

REGENXBIO Inc. RGNX

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,593 of 2,925

Why it scores 26Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$108.02M

Quarter to Jun 30

Net income

$22.71M

Quarter to Jun 30

Free cash flow

$-63.00M

Quarter to Jun 30

Operating margin

27.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$504.61M total
BlackRock, Inc.
$76.64M+10.6%
Redmile Group, LLC
$52.34M0.0%
STATE STREET CORP
$35.59M+8.8%
JPMORGAN CHASE & CO
$26.19M-36.4%
VANGUARD CAPITAL MANAGEMENT LLC
$25.25M+5.0%
MORGAN STANLEY
$23.40M-5.5%
GOLDMAN SACHS GROUP INC
$17.03M-22.7%
AQR CAPITAL MANAGEMENT LLC
$16.51M+31.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$16.24M+33.0%
MARSHALL WACE, LLP
$15.39MNew
GEODE CAPITAL MANAGEMENT, LLC
$14.87M+9.1%
Integral Health Asset Management, LLC
$9.58M-46.7%
Nuveen, LLC
$8.87M+27.1%
DIMENSIONAL FUND ADVISORS LP
$8.76M-27.6%
D. E. Shaw & Co., Inc.
$8.54M+149.2%
TWO SIGMA INVESTMENTS, LP
$8.02M+20.7%
CITADEL ADVISORS LLC
$8.01MNew
STIFEL FINANCIAL CORP
$6.72M+42.8%
BANK OF AMERICA CORP /DE/
$6.21M+59.6%
22NW, LP
$5.90M0.0%
MILLENNIUM MANAGEMENT LLC
$5.76M+68.6%
Pale Fire Capital SE
$5.59M-5.6%
NORTHERN TRUST CORP
$5.05M+7.2%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.75M+1.5%
LAZARD ASSET MANAGEMENT LLC
$4.44MNew
See all 166 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RGNX

Earnings Per Share

13fpro.ai/company/RGNX

Loading ratio trend…

RGNX key financials by period

Reported revenue, net income and operating margin by fiscal year, from REGENXBIO Inc.'s annual filings on SEC EDGAR.

REGENXBIO Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$170.4M$-193.9M-94.6%
FY 2024$83.3M$-227.1M—
FY 2023$90.2M$-263.5M—
FY 2022$112.7M$-280.3M—
FY 2021$470.3M$127.8M34.0%
FY 2020$154.6M$-111.3M-77.1%
Source: RGNX filings on SEC EDGAR →

Companies similar to RGNX

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

RGNX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About REGENXBIO Inc. (RGNX): stock profile, AI score and financials

REGENXBIO Inc. (RGNX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RGNX at 26.3/100 on a composite quality score built from its SEC filings, placing it at rank #2,593 of 2,925 stocks — the bottom half of the AI-ranked universe. RGNX scores in the top quartile across revenue growth (91.9). Areas of concern include institutional flow (1.4) and balance sheet strength (5.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), REGENXBIO Inc. reports quarterly revenue of $108.0M, net income of $22.7M, an operating margin of 27.1%. Top institutional holders of RGNX by reported 13-F value include BlackRock, Redmile Group, STATE STREET, based on the most recent SEC filings. RGNX trades on the Nasdaq exchange and files with the SEC under CIK 1590877. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENXBIO Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1590877 →